课题基金 / 基金详情

Surface modified metal implants using doped hydroxyapatite

Surface modified metal implants using doped hydroxyapatite
使用掺杂羟基磷灰石进行表面改性的金属植入物
批准号:
9313617
负责人:
SUSMITA BOSE
金额:
$31.98万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-01 至 2019-07-31

项目摘要

项目成果

SUSMITA BOSE的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):骨骼缺乏的肌肉骨骼疾病,以及髋关节和膝关节问题等疾病是当今存在的常见的重要人类健康状况。在这些情况下,重建通常伴随着人工金属植入物,必须与周围的骨融合。本拨款申请的目的是将羟基磷灰石(HA)涂层与选定的掺杂剂和小分子结合在钛(Ti)基质上,通过增强组织材料的相互作用来提高生物活性。本研究的长期目标是通过设计成分分级、小分子/离子掺杂的纳米级涂层来开发新型ha涂层金属植入物,用于年轻患者和髋关节、肩部或膝关节植入物的翻修手术,通过增强骨整合来改善体内寿命。我们的设计目标是:1)通过控制化学和微观结构来增强界面力学性能;2)提高ha涂层金属植入物的生物活性并引入骨诱导性。我们的初步数据表明,激光和射频感应等离子体在Ti表面处理HA和磷酸三钙(TCP,另一种常用的磷酸钙相)涂层可以消除离散和弱的金属-陶瓷界面,提高涂层的界面强度。我们假设,优化激光和等离子体加工参数以及掺杂化学可以产生具有强界面的组合梯度HA涂层,从而提高涂层在金属植入体体内的机械稳定性。在Aim 1中,我们将研究它们的梯度微观结构、物理力学性能。我们将测试并比较我们的植入物与Biomet公司的市售涂层植入物,请参阅附件的支持信。根据我们的初步数据,我们发现所选择的掺杂剂可以促进大鼠早期骨组织整合,并在体外控制人成骨细胞(OB)和破骨细胞(OC)的活性。由于Si可以诱导血管生成,Sr和Mg降低OC活性,Mg和Zn提高OB活性,我们假设掺杂剂的存在会调节体外生物相容性和体内骨组织整合。在目标2中,我们将评估掺杂HA涂层Ti样品,其界面机械强度为目前ASTM标准的> - 15mpa,在大鼠和兔模型中在股骨远端产生髓内缺陷。我们的初步数据表明,HA和TCP可用于装载和释放小分子药物和蛋白质,例如阿仑膦酸盐(AD,一种双膦酸盐,BP,药物)/模型蛋白牛血清白蛋白(BSA), AD的存在可增加局部骨密度。我们的假设是,掺杂剂将改善早期骨细胞附着和体内组织与涂层的整合,而小分子药物,如阿仑膦酸钠,将局部增加
英文摘要
DESCRIPTION (provided by applicant): Musculoskeletal disorders with bone deficiencies, and conditions such as hip and knee problems are common important human health conditions that exist today. In these situations, reconstruction is often accompanied by an artificial metallic implant that must integrate with the surrounding bone. The objective of this grant application is focused on hydroxyapatite (HA) coating with selected dopants and small molecules on Titanium (Ti) substrates to improve bioactivity with enhanced tissue material interactions. The long-term goal of this research is to develop novel HA-coated metal implants by designing compositionally graded, small molecule / ionically doped nanoscale coatings for younger patients and revision surgeries in hip, shoulder or knee implants, with improved in vivo lifetime due to enhanced osseointegration. Our design goals are to: 1) enhanced interfacial mechanical properties via controlled chemistry and microstructure and 2) improve bioactivity and introduce osteoinductivity in HA-coated metal implants. Our preliminary data show that laser and RF induction plasma processed HA and tricalcium phosphate (TCP, another commonly used calcium phosphate phase) coating on Ti can eliminate discrete and weak metal- ceramic interface to improve interfacial strength of coatings. We hypothesize that optimized laser and plasma processing parameters along with dopant chemistry can produce a compositionally graded HA coating with strong interface to improve mechanical stability of coatings in vivo in metal implants. In Aim 1, we will study their gradient microstructure, physical and mechanical properties. We will test and compare our implants with commercially available coated implants from Biomet Inc., please see the attached support letter. Based on our preliminary data, we show that selected dopants can promote early-stage bone tissue integration in rat and control human osteoblast (OB) and osteoclast (OC) activities in vitro. Since Si can induce angiogenesis, Sr and Mg reduce OC activities, Mg and Zn enhance OB activities, we hypothesize that the presence of dopants will regulate in vitro biocompatibility as well as in vivo bone tissue integration. In Aim 2, we will evaluate doped HA coated Ti samples, with interfacial mechanical strength >15 MPa per current ASTM standard, creating an intramedullary defect in the distal femur in rat and rabbit models. Our preliminary data shows that HA and TCP can be used in loading and releasing small molecule drug and protein, e.g. alendronate (AD, a bisphosphonate, BP, drug) / model protein bovine serum albumin (BSA) and presence of AD can increase local bone density. Our hypothesis is that the dopants will improve early stage bone cell attachment and in vivo tissue integration with the coating while the small molecule drug, e.g. Alendronate, will locally increase bone density after implantation, especially in revision surgeries. In Aim 3, we will determine the bioactivity, dopant / drug release kinetics in vitro, followed by in vivo studies to evaluate bone tissue integration of these coatings using intramedullary defects in rat distal femurs. The scientific understanding from this program will lead to improved long-term fixation of cementless joint replacements and other metal implants.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
3D Printed Calcium Phosphate Scaffolds with Natural Medicinal Compounds for Dental Applications
  • 批准号:
    10220015
  • 项目类别:
  • 资助金额:
    $35.12万
  • 财政年份:
    2020
  • 负责人:
    SUSMITA BOSE
  • 依托单位:
3D Printed Calcium Phosphate Scaffolds with Natural Medicinal Compounds for Dental Applications
  • 批准号:
    10053065
  • 项目类别:
  • 资助金额:
    $35.08万
  • 财政年份:
    2020
  • 负责人:
    SUSMITA BOSE
  • 依托单位:
3D Printed Calcium Phosphate Scaffolds with Natural Medicinal Compounds for Dental Applications
  • 批准号:
    10450826
  • 项目类别:
  • 资助金额:
    $34.72万
  • 财政年份:
    2020
  • 负责人:
    SUSMITA BOSE
  • 依托单位:
3D Printed Calcium Phosphate Scaffolds with Natural Medicinal Compounds for Dental Applications
  • 批准号:
    10665696
  • 项目类别:
  • 资助金额:
    $35.02万
  • 财政年份:
    2020
  • 负责人:
    SUSMITA BOSE
  • 依托单位:
海外基金